Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Jung Sun | - |
dc.contributor.author | Her, Sung-Ho | - |
dc.contributor.author | Baek, Ju Yeal | - |
dc.contributor.author | Park, Mahn-Won | - |
dc.contributor.author | Kim, Hyoung Doo | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.contributor.author | Ahn, Young Keun | - |
dc.contributor.author | Chae, Shung Chull | - |
dc.contributor.author | Hur, Seung Ho | - |
dc.contributor.author | Hong, Taek Jong | - |
dc.contributor.author | Kim, Young Jo | - |
dc.contributor.author | Seong, In Whan | - |
dc.contributor.author | Chae, Jei Keon | - |
dc.contributor.author | Rhew, Jay Young | - |
dc.contributor.author | Chae, In Ho | - |
dc.contributor.author | Cho, Myeong Chan | - |
dc.contributor.author | Bae, Jang Ho | - |
dc.contributor.author | Rha, Seung Woon | - |
dc.contributor.author | Kim, Chong Jim | - |
dc.contributor.author | Choi, Donghoon | - |
dc.contributor.author | Jang, Yang Soo | - |
dc.contributor.author | Yoon, Junghan | - |
dc.contributor.author | Chung, Wook Sung | - |
dc.contributor.author | Cho, Jeong Gwan | - |
dc.contributor.author | Seung, Ki Bae | - |
dc.contributor.author | Park, Seung Jung | - |
dc.date.accessioned | 2021-09-07T23:01:48Z | - |
dc.date.available | 2021-09-07T23:01:48Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2010-11 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/115355 | - |
dc.description.abstract | The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | HIGH-RISK PATIENTS | - |
dc.subject | UNFRACTIONATED HEPARIN | - |
dc.subject | PLATELET-AGGREGATION | - |
dc.subject | ENOXAPARIN | - |
dc.subject | SAFETY | - |
dc.subject | ABCIXIMAB | - |
dc.subject | EFFICACY | - |
dc.subject | OUTCOMES | - |
dc.subject | REVASCULARIZATION | - |
dc.subject | ACTIVATION | - |
dc.title | Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung Woon | - |
dc.identifier.doi | 10.3346/jkms.2010.25.11.1601 | - |
dc.identifier.scopusid | 2-s2.0-78449303538 | - |
dc.identifier.wosid | 000284233100009 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.25, no.11, pp.1601 - 1608 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 25 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1601 | - |
dc.citation.endPage | 1608 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001492932 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | HIGH-RISK PATIENTS | - |
dc.subject.keywordPlus | UNFRACTIONATED HEPARIN | - |
dc.subject.keywordPlus | PLATELET-AGGREGATION | - |
dc.subject.keywordPlus | ENOXAPARIN | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | ABCIXIMAB | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | REVASCULARIZATION | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordAuthor | Myocardial Infarction | - |
dc.subject.keywordAuthor | Heparin | - |
dc.subject.keywordAuthor | Blood Platelets | - |
dc.subject.keywordAuthor | Prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.